Cardiff Oncology (NASDAQ:CRDF) Director Gary Pace Purchases 30,000 Shares of Stock

Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Gary Pace purchased 30,000 shares of Cardiff Oncology stock in a transaction dated Thursday, June 18th. The stock was bought at an average cost of $1.22 per share, for a total transaction of $36,600.00. Following the completion of the purchase, the director directly owned 1,356,376 shares in the company, valued at approximately $1,654,778.72. This trade represents a 2.26% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Cardiff Oncology Stock Performance

NASDAQ:CRDF opened at $1.30 on Tuesday. The stock has a market capitalization of $88.88 million, a P/E ratio of -1.94 and a beta of 1.36. The company has a 50 day moving average price of $1.62 and a 200 day moving average price of $1.97. Cardiff Oncology, Inc. has a fifty-two week low of $1.16 and a fifty-two week high of $4.55.

Cardiff Oncology (NASDAQ:CRDF) last posted its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). Cardiff Oncology had a negative net margin of 8,527.43% and a negative return on equity of 95.51%. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. Research analysts forecast that Cardiff Oncology, Inc. will post -0.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on CRDF. Weiss Ratings restated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Monday, May 18th. Wall Street Zen downgraded shares of Cardiff Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. TD Cowen cut shares of Cardiff Oncology from a “buy” rating to a “hold” rating in a research report on Monday, June 1st. Piper Sandler decreased their price target on shares of Cardiff Oncology from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Finally, HC Wainwright downgraded shares of Cardiff Oncology from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Three equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.75.

Hedge Funds Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Capital Advisors Wealth Management LLC purchased a new position in Cardiff Oncology in the fourth quarter valued at $30,000. Tamar Securities LLC acquired a new position in shares of Cardiff Oncology during the 4th quarter worth about $32,000. Brooklyn Investment Group purchased a new position in shares of Cardiff Oncology in the 3rd quarter valued at about $26,000. R Squared Ltd acquired a new stake in shares of Cardiff Oncology during the 4th quarter worth about $36,000. Finally, Engineers Gate Manager LP purchased a new stake in Cardiff Oncology during the second quarter worth approximately $43,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.